ArticleJournal of pain research2025
Mechanistic Study on the Therapeutic Effects of Juanbi Lijieqing Formula in a Rat Model of Gouty Arthritis with Hyperuricemia.
Article in Journal of pain research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study evaluated the therapeutic effects and underlying mechanisms of Juanbi Lijieqing Formula (JBLJQF) in a rat model of gouty arthritis with hyperuricemia. Methods: Forty-two rats were randomly assigned to seven groups: control, model, etoricoxib, benzbromarone, and low-, medium-, and high-dose JBLJQF. General condition, joint swelling, behavioral performance, biochemical markers, and histopathology were assessed. Urate Anion Transporter 1(URAT1) expression was examined via immunofluorescence and Western blot. Results: JBLJQF improved general condition, reduced joint swelling, and alleviated kidney damage. Medium- and high-dose groups showed enhanced pain threshold and locomotor activity. Serum uric acid, TNF-α, and IL-1β levels were significantly decreased. URAT1 expression was downregulated, suggesting reduced renal urate reabsorption. Conclusion: JBLJQF exerts anti-inflammatory, uric acid-lowering, and organ-protective effects in gouty arthritis with hyperuricemia, highlighting its potential for clinical application.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.